Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rebecca Suk Heist, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Dias-Santagata D, Heist RS, Bard AZ, da Silva AFL, Dagogo-Jack I, Nardi V, Ritterhouse LL, Spring LM, Jessop N, Farahani AA, Mino-Kenudson M, Allen J, Goyal L, Parikh A, Misdraji J, Shankar G, Jordan JT, Martinez-Lage M, Frosch M, Graubert T, Fathi AT, Hobbs GS, Hasserjian RP, Raje N, Abramson J, Schwartz JH, Sullivan RJ, Miller D, Hoang MP, Isakoff S, Ly A, Bouberhan S, Watkins J, Oliva E, Wirth L, Sadow PM, Faquin W, Cote GM, Hung YP, Gao X, Wu CL, Garg S, Rivera M, Le LP, John Iafrate A, Juric D, Hochberg EP, Clark J, Bardia A, Lennerz JK. Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network. Oncologist. 2022 Nov 03; 27(11):930-939. PMID: 35852437; PMCID: PMC9632318.
    Citations:    Fields:    
  2. Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Oct 26; JCO2200739. PMID: 36288547.
    Citations:    Fields:    
  3. Cooper AJ, Muzikansky A, Lennerz J, Narinesingh F, Mino-Kenudson M, Hung YP, Piotrowska Z, Dagogo-Jack I, Sequist LV, Gainor JF, Lin JJ, Heist RS. Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC. JTO Clin Res Rep. 2022 Sep; 3(9):100390. PMID: 36118132.
    Citations:    
  4. Sabari JK, Velcheti V, Shimizu K, Strickland MR, Heist RS, Singh M, Nayyar N, Giobbie-Hurder A, Digumarthy SR, Gainor JF, Rajan AP, Nieblas-Bedolla E, Burns AC, Hallin J, Olson P, Christensen JG, Kurz SC, Brastianos PK, Wakimoto H. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2022 08 02; 28(15):3318-3328. PMID: 35404402.
    Citations:    Fields:    
  5. Choy E, Cote GM, Michaelson MD, Wirth L, Gainor JF, Muzikansky A, Sequist LV, Sullivan RJ, Fidias PM, Shaw A, Heist RS. Phase II Study of Cabozantinib in Patients With Bone Metastasis. Oncologist. 2022 07 05; 27(7):600-606. PMID: 35524758; PMCID: PMC9256024.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  6. Bauer T, Cho BC, Heist R, Bazhenova L, Werner T, Goel S, Kim DW, Adkins D, Carvajal RD, Alva A, Eaton K, Wang J, Liu Y, Yan X, Christensen J, Neuteboom S, Chao R, Pant S. First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. Invest New Drugs. 2022 10; 40(5):990-1000. PMID: 35767205; PMCID: PMC9395446.
    Citations:    Fields:    
  7. Kim DW, Gadgeel S, Gettinger SN, Riely GJ, Oxnard GR, Mekhail T, Schmid P, Dowlati A, Heist RS, Wozniak AJ, Singh J, Cha E, Spahn J, Ou SI. Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC. JTO Clin Res Rep. 2022 Aug; 3(8):100367. PMID: 35875467; PMCID: PMC9304608.
    Citations:    
  8. Schneider JL, Muzikansky A, Lin JJ, Krueger EA, Lennes IT, Jacobson JO, Cheng M, Heist RS, Piotrowska Z, Gainor JF, Shaw AT, Dagogo-Jack I. A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib. JTO Clin Res Rep. 2022 Jul; 3(7):100347. PMID: 35815322; PMCID: PMC9257415.
    Citations:    
  9. Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med. 2022 07 14; 387(2):120-131. PMID: 35658005.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  10. Dagogo-Jack I, Oxnard GR, Evangelist M, Digumarthy SR, Lin JJ, Gainor JF, Murphy JF, Rabin MS, Heist RS, Muzikansky A, Shaw AT. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse. JCO Precis Oncol. 2022 05; 6:e2100522. PMID: 35584349.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  11. Piper-Vallillo AJ, Rotow JK, Aredo JV, Shaverdashvili K, Luo J, Carlisle JW, Husain H, Muzikansky A, Heist RS, Rangachari D, Ramalingam SS, Wakelee HA, Yu HA, Sequist LV, Bauml JM, Neal JW, Piotrowska Z. High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO Clin Res Rep. 2022 Jun; 3(6):100328. PMID: 35637759; PMCID: PMC9142556.
    Citations: 1     
  12. Remon J, Lacas B, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJM, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, Heist RS, Planchard D, Pignon JP, Besse B. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. Eur J Cancer. 2022 05; 166:112-125. PMID: 35286903.
    Citations:    Fields:    Translation:Humans
  13. Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Angevin E, Hong DS, Rybkin II, Barve M, Bauer TM, Delmonte A, Dunbar M, Motwani M, Parikh A, Noon E, Wu J, Blot V, Kelly K. A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. JTO Clin Res Rep. 2022 Jan; 3(1):100262. PMID: 35005654; PMCID: PMC8717236.
    Citations:    
  14. Hu H, Piotrowska Z, Hare PJ, Chen H, Mulvey HE, Mayfield A, Noeen S, Kattermann K, Greenberg M, Williams A, Riley AK, Wilson JJ, Mao YQ, Huang RP, Banwait MK, Ho J, Crowther GS, Hariri LP, Heist RS, Kodack DP, Pinello L, Shaw AT, Mino-Kenudson M, Hata AN, Sequist LV, Benes CH, Niederst MJ, Engelman JA. Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell. 2021 11 08; 39(11):1531-1547.e10. PMID: 34624218; PMCID: PMC8578451.
    Citations: 10     Fields:    Translation:HumansCells
  15. Camidge DR, Morgensztern D, Heist RS, Barve M, Vokes E, Goldman JW, Hong DS, Bauer TM, Strickler JH, Angevin E, Motwani M, Parikh A, Sun Z, Bach BA, Wu J, Komarnitsky PB, Kelly K. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021 11 01; 27(21):5781-5792. PMID: 34426443.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  16. Wo JY, Clark JW, Eyler CE, Mino-Kenudson M, Klempner SJ, Allen JN, Keane FK, Parikh AR, Roeland E, Drapek LC, Ryan DP, Corcoran RB, Van Seventer E, Fetter IJ, Shahzade HA, Khandekar MJ, Lanuti M, Morse CR, Heist RS, Ulysse CA, Christopher B, Baglini C, Yeap BY, Mullen JT, Hong TS. Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clin Cancer Res. 2021 12 01; 27(23):6343-6353. PMID: 34330715.
    Citations: 1     Fields:    Translation:Humans
  17. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021 08 07; 398(10299):535-554. PMID: 34273294.
    Citations: 89     Fields:    Translation:Humans
  18. Wu MY, Zhang EW, Strickland MR, Mendoza DP, Lipkin L, Lennerz JK, Gainor JF, Heist RS, Digumarthy SR. Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation. Cancers (Basel). 2021 Jul 16; 13(14). PMID: 34298783.
    Citations:    
  19. Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, Jacobson JO, Yang X, Persky NS, Root DE, Lowder KE, Feng H, Zhang SS, Haigis KM, Hung YP, Sholl LM, Wolpin BM, Wiese J, Christiansen J, Lee J, Schrock AB, Lim LP, Garg K, Li M, Engstrom LD, Waters L, Lawson JD, Olson P, Lito P, Ou SI, Christensen JG, Jänne PA, Aguirre AJ. Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med. 2021 06 24; 384(25):2382-2393. PMID: 34161704; PMCID: PMC8864540.
    Citations: 61     Fields:    Translation:HumansCells
  20. Brastianos PK, Kim AE, Wang N, Lee EQ, Ligibel J, Cohen JV, Chukwueke UN, Mahar M, Oh K, White MD, Shih HA, Forst D, Gainor JF, Heist RS, Gerstner ER, Batchelor TT, Lawrence D, Ryan DP, Iafrate AJ, Giobbie-Hurder A, Santagata S, Carter SL, Cahill DP, Sullivan RJ. Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nat Cancer. 2021 05; 2(5):498-502. PMID: 35122016.
    Citations: 5     Translation:Humans
  21. Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, Siravegna G, Bar-Peled L, Hata AN, Heist RS, Corcoran RB. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Cancer Discov. 2021 08; 11(8):1913-1922. PMID: 33824136; PMCID: PMC8338755.
    Citations: 40     Fields:    Translation:Humans
  22. Cleary JM, Wang V, Heist RS, Kopetz ES, Mitchell EP, Zwiebel JA, Kapner KS, Chen HX, Li S, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Meric-Bernstam F, Dillmon MS, Williams PM, Hamilton SR, Conley BA, Aguirre AJ, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. Clin Cancer Res. 2021 06 01; 27(11):2996-3004. PMID: 33637626; PMCID: PMC8542423.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  23. Dagogo-Jack I, Moonsamy P, Gainor JF, Lennerz JK, Piotrowska Z, Lin JJ, Lennes IT, Sequist LV, Shaw AT, Goodwin K, Stevens SE, Do A, Digumarthy SR, Price K, Muzikansky A, Hata AN, Heist RS. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. J Thorac Oncol. 2021 05; 16(5):850-859. PMID: 33545388; PMCID: PMC8922989.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  24. Piper-Vallillo AJ, Mooradian MJ, Meador CB, Yeap BY, Peterson J, Sakhi M, Do A, Zubiri L, Stevens S, Vaughn J, Goodwin K, Gavralidis A, Willers H, Miller A, Farago A, Piotrowska Z, Lin JJ, Dagogo-Jack I, Lennes IT, Sequist LV, Temel JS, Heist RS, Digumarthy S, Reynolds KL, Gainor JF. Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations. JTO Clin Res Rep. 2021 Jan; 2(1):100124. PMID: 33205053; PMCID: PMC7659804.
    Citations: 3     
  25. Chaudhary SP, Kwak EL, Hwang KL, Lennerz JK, Corcoran RB, Heist RS, Russo AL, Parikh A, Borger DR, Blaszkowsky LS, Faris JE, Murphy JE, Azzoli CG, Roeland EJ, Goyal L, Allen J, Mullen JT, Ryan DP, Iafrate AJ, Klempner SJ, Clark JW, Hong TS. Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers. Oncologist. 2020 11; 25(11):e1691-e1700. PMID: 32820577.
    Citations: 1     Fields:    Translation:Humans
  26. Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 09 03; 383(10):944-957. PMID: 32877583.
    Citations: 134     Fields:    Translation:HumansCTClinical Trials
  27. Hellmann MD, Gettinger S, Chow LQM, Gordon M, Awad MM, Cha E, Gong X, Zhou G, Walker C, Leopold L, Heist RS. Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer. Int J Cancer. 2020 10 01; 147(7):1963-1969. PMID: 32141617.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  28. Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, D'Amelio AM, Ellis C, Ibrahim N, Yan L. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. 2020 04; 85(4):673-683. PMID: 32062691.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  29. Drilon A, Clark JW, Weiss J, Ou SI, Camidge DR, Solomon BJ, Otterson GA, Villaruz LC, Riely GJ, Heist RS, Awad MM, Shapiro GI, Satouchi M, Hida T, Hayashi H, Murphy DA, Wang SC, Li S, Usari T, Wilner KD, Paik PK. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020 01; 26(1):47-51. PMID: 31932802; PMCID: PMC8500676.
    Citations: 80     Fields:    Translation:Humans
  30. Goyal L, Chaudhary SP, Kwak EL, Abrams TA, Carpenter AN, Wolpin BM, Wadlow RC, Allen JN, Heist R, McCleary NJ, Chan JA, Goessling W, Schrag D, Ng K, Enzinger PC, Ryan DP, Clark JW. A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. Invest New Drugs. 2020 10; 38(5):1533-1539. PMID: 31898183.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  31. Gainor JF, Stevens SE, Willers H, Shih HA, Heist RS. Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non-Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification. J Thorac Oncol. 2020 01; 15(1):e8-e10. PMID: 31864558.
    Citations:    Fields:    Translation:Humans
  32. Digumarthy SR, Mendoza DP, Zhang EW, Lennerz JK, Heist RS. Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. Cancers (Basel). 2019 Dec 17; 11(12). PMID: 31861060; PMCID: PMC6966679.
    Citations: 10     
  33. Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020 01; 10(1):40-53. PMID: 31732494; PMCID: PMC6954326.
    Citations: 69     Fields:    Translation:HumansCTClinical Trials
  34. Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, Zhong J, Rangachari D, Barbie DA, Phat S, Myers DT, Morris R, Kem M, Dubash TD, Kennedy EA, Digumarthy SR, Sequist LV, Hata AN, Maheswaran S, Haber DA, Lawrence MS, Shaw AT, Mino-Kenudson M, Dyson NJ, Drapkin BJ. Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discov. 2019 10; 9(10):1372-1387. PMID: 31416802.
    Citations: 48     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  35. Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019 07; 133:96-102. PMID: 31200835.
    Citations: 32     Fields:    Translation:Humans
  36. Cheng J, Cao Y, MacLeay A, Lennerz JK, Baig A, Frazier RP, Lee J, Hu K, Pacula M, Meneses E, Robinson H, Batten JM, Brastianos PK, Heist RS, Bardia A, Le LP, Iafrate AJ. Clinical Validation of a Cell-Free DNA Gene Panel. J Mol Diagn. 2019 07; 21(4):632-645. PMID: 31026600.
    Citations: 6     Fields:    Translation:Humans
  37. Voss MH, Hierro C, Heist RS, Cleary JM, Meric-Bernstam F, Tabernero J, Janku F, Gandhi L, Iafrate AJ, Borger DR, Ishii N, Hu Y, Kirpicheva Y, Nicolas-Metral V, Pokorska-Bocci A, Vaslin Chessex A, Zanna C, Flaherty KT, Baselga J. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clin Cancer Res. 2019 05 01; 25(9):2699-2707. PMID: 30745300; PMCID: PMC9014845.
    Citations: 39     Fields:    Translation:HumansCellsCTClinical Trials
  38. Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, Evans TL, Costa DB, Wakelee HA, Heist RS, Shapiro MA, Muzikansky A, Murthy S, Lanuti M, Rusch VW, Kris MG, Sequist LV. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol. 2019 01 10; 37(2):97-104. PMID: 30444685; PMCID: PMC6524649.
    Citations: 65     Fields:    Translation:HumansCTClinical Trials
  39. Schram AM, Gandhi L, Mita MM, Damstrup L, Campana F, Hidalgo M, Grande E, Hyman DM, Heist RS. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours. Br J Cancer. 2018 12; 119(12):1471-1476. PMID: 30425349; PMCID: PMC6288157.
    Citations: 26     Fields:    Translation:HumansCTClinical Trials
  40. Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 11 20; 36(33):3298-3306. PMID: 30285518.
    Citations: 32     Fields:    Translation:HumansCTClinical Trials
  41. Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Sands J, Santana-Davila R, Williams CC, Hoffmann KG, Hughes M. NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018 10; 16(10):1171-1182. PMID: 30323087.
    Citations: 72     Fields:    Translation:Humans
  42. Piotrowska Z, Costa DB, Oxnard GR, Huberman M, Gainor JF, Lennes IT, Muzikansky A, Shaw AT, Azzoli CG, Heist RS, Sequist LV. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. Ann Oncol. 2018 10 01; 29(10):2092-2097. PMID: 30351341.
    Citations: 26     Fields:    Translation:HumansCTClinical Trials
  43. Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539. PMID: 30257958; PMCID: PMC6279502.
    Citations: 133     Fields:    Translation:HumansCells
  44. Lin JJ, Chin E, Yeap BY, Ferris LA, Kamesan V, Lennes IT, Sequist LV, Heist RS, Mino-Kenudson M, Gainor JF, Shaw AT. Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 01; 14(1):135-140. PMID: 30205166; PMCID: PMC6309637.
    Citations: 30     Fields:    Translation:Humans
  45. Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodi FS, Ready NE, Zhang W, Wallin J, Funke R, Waterkamp D, Foster P, Iizuka K, Powderly J. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer. 2018 09; 101:114-122. PMID: 30053670.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  46. Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018. PMID: 30370396; PMCID: PMC6200882.
    Citations: 11     Fields:    
  47. Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, Dardaei L, Prutisto-Chang K, Dagogo-Jack I, Timofeevski S, Hubbeling H, Gainor JF, Ferris LA, Riley AK, Kattermann KE, Timonina D, Heist RS, Iafrate AJ, Benes CH, Lennerz JK, Mino-Kenudson M, Engelman JA, Johnson TW, Hata AN, Shaw AT. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018 06; 8(6):714-729. PMID: 29650534; PMCID: PMC5984716.
    Citations: 76     Fields:    Translation:HumansAnimalsCells
  48. Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC, Leming P, Geese WJ, Yoon D, Li A, Brahmer J. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol. 2018 06 10; 36(17):1675-1684. PMID: 29570421.
    Citations: 258     Fields:    Translation:HumansCTClinical Trials
  49. Drapkin BJ, George J, Christensen CL, Mino-Kenudson M, Dries R, Sundaresan T, Phat S, Myers DT, Zhong J, Igo P, Hazar-Rethinam MH, Licausi JA, Gomez-Caraballo M, Kem M, Jani KN, Azimi R, Abedpour N, Menon R, Lakis S, Heist RS, Büttner R, Haas S, Sequist LV, Shaw AT, Wong KK, Hata AN, Toner M, Maheswaran S, Haber DA, Peifer M, Dyson N, Thomas RK, Farago AF. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. Cancer Discov. 2018 05; 8(5):600-615. PMID: 29483136; PMCID: PMC6369413.
    Citations: 68     Fields:    Translation:HumansAnimals
  50. Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, Ackil J, Stevens S, Dardaei L, Yoda S, Hubbeling H, Digumarthy SR, Riester M, Hata AN, Sequist LV, Lennes IT, Iafrate AJ, Heist RS, Azzoli CG, Farago AF, Engelman JA, Lennerz JK, Benes CH, Leary RJ, Shaw AT, Gainor JF. Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. JCO Precis Oncol. 2018; 2018. PMID: 29376144; PMCID: PMC5785105.
    Citations: 49     Fields:    
  51. Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol. 2017 Aug 01; 3(8):1043-1050. PMID: 28208174; PMCID: PMC5553624.
    Citations: 39     Fields:    Translation:HumansCTClinical Trials
  52. Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L, Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Clin Cancer Res. 2017 Oct 01; 23(19):5711-5719. PMID: 28679770.
    Citations: 37     Fields:    Translation:HumansCTClinical Trials
  53. Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017 Aug 20; 35(24):2790-2797. PMID: 28548889.
    Citations: 46     Fields:    Translation:HumansCTClinical Trials
  54. Dagogo-Jack I, Fabrizio D, Lennerz J, Schrock AB, Young L, Mino-Kenudson M, Digumarthy SR, Heist RS, Ali SM, Miller VA, Shaw AT. Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. J Thorac Oncol. 2017 10; 12(10):e155-e157. PMID: 28499860.
    Citations: 1     Fields:    Translation:Humans
  55. Piotrowska Z, Stirling K, Heist R, Campo M, Rizzo C, Digumarthy SR, Lanuti M, Fintelmann FJ, Lennes I, Farago A, Gainor J, Azzoli CG, Temel J, Mino-Kenudson M, Dias-Santagata D, Corcoran R, Shaw A, Engelman JA, Hata A, Sequist LV. Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy. Int J Radiat Oncol Biol Phys. 2017 May 01; 98(1):220. PMID: 28586967.
    Citations:    Fields:    
  56. Mahadevan D, Mita M, Richards D, McClay E, Heist RS, Kumar A, Sundararajan S, Naing A. Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients. Cancer Chemother Pharmacol. 2017 04; 79(4):681-688. PMID: 28289865.
    Citations:    Fields:    Translation:HumansCellsCTClinical Trials
  57. Heist RS. First-Line Systemic Therapy for Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am. 2017 02; 31(1):59-70. PMID: 27912834.
    Citations: 6     Fields:    Translation:Humans
  58. Spreafico A, Coate L, Zhai R, Xu W, Chen ZF, Chen Z, Patel D, Tse B, Brown MC, Heist RS, Dodbiba L, Teichman J, Kulke M, Su L, Eng L, Knox J, Wong R, Darling GE, Christiani DC, Liu G. Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival. Cancer Epidemiol. 2017 04; 47:28-34. PMID: 28088657.
    Citations: 11     Fields:    Translation:Humans
  59. Wakelee H, Patel JD, Heist R, Balmanoukian A, Besse B, Felip E, Carcereny Costa E, Chow LQ, Koczywas M, Garassino MC, Christoph D, Toh CK, Johnson ML, Chaft J, Kurata T, Qiu J, Kowanetz M, Coleman S, Mocci S, Sandler A, Gettinger SN, Peters S. ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology. J Thorac Oncol. 2016 11; 11(11S):S251-S252. PMID: 27969443.
    Citations: 6     Fields:    
  60. Bauman JR, Piotrowska Z, Muzikansky A, Gallagher E, Scribner E, Temel B, Sequist LV, Heist RS, Temel JS. End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations. J Palliat Med. 2016 12; 19(12):1316-1319. PMID: 27626514.
    Citations: 4     Fields:    Translation:Humans
  61. Campo M, Gerber D, Gainor JF, Heist RS, Temel JS, Shaw AT, Fidias P, Muzikansky A, Engelman JA, Sequist LV. Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. J Thorac Oncol. 2016 11; 11(11):2022-2026. PMID: 27553514.
    Citations: 37     Fields:    Translation:Humans
  62. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133. PMID: 27432227; PMCID: PMC5050111.
    Citations: 373     Fields:    Translation:HumansCells
  63. Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, Dias-Santagata D, Clark JW, Engelman JA, Shaw AT, Iafrate AJ. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2016 08; 11(8):1242-1245. PMID: 27343442.
    Citations: 55     Fields:    Translation:Humans
  64. Sequist LV, Piotrowska Z, Niederst MJ, Heist RS, Digumarthy S, Shaw AT, Engelman JA. Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. JAMA Oncol. 2016 Apr; 2(4):541-3. PMID: 26720284.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
  65. Heist RS, Shim HS, Gingipally S, Mino-Kenudson M, Le L, Gainor JF, Zheng Z, Aryee M, Xia J, Jia P, Jin H, Zhao Z, Pao W, Engelman JA, Iafrate AJ. MET Exon 14 Skipping in Non-Small Cell Lung Cancer. Oncologist. 2016 Apr; 21(4):481-6. PMID: 27022036.
    Citations: 34     Fields:    Translation:Humans
  66. Hayano K, Kulkarni NM, Duda DG, Heist RS, Sahani DV. Exploration of Imaging Biomarkers for Predicting Survival of Patients With Advanced Non-Small Cell Lung Cancer Treated With Antiangiogenic Chemotherapy. AJR Am J Roentgenol. 2016 May; 206(5):987-93. PMID: 26934729.
    Citations: 14     Fields:    Translation:Humans
  67. Shim HS, Kenudson M, Zheng Z, Liebers M, Cha YJ, Hoang Ho Q, Onozato M, Phi Le L, Heist RS, Iafrate AJ. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. J Thorac Oncol. 2015 Aug; 10(8):1156-62. PMID: 26200269.
    Citations: 66     Fields:    Translation:Humans
  68. Duda DG, Heist RS, Sahani DV, Stylianopoulos T, Engelman JA, Jain RK. Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):E3454. PMID: 26080434; PMCID: PMC4500270.
    Citations:    Fields:    Translation:Humans
  69. Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30; 372(18):1700-9. PMID: 25923550.
    Citations: 250     Fields:    Translation:HumansCTClinical Trials
  70. O'Brien TD, Jia P, Xia J, Saxena U, Jin H, Vuong H, Kim P, Wang Q, Aryee MJ, Mino-Kenudson M, Engelman JA, Le LP, Iafrate AJ, Heist RS, Pao W, Zhao Z. Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. Methods. 2015 Jul 15; 83:118-27. PMID: 25913717.
    Citations: 15     Fields:    Translation:HumansCells
  71. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 Jun 20; 33(18):2004-12. PMID: 25897158; PMCID: PMC4672027.
    Citations: 492     Fields:    Translation:HumansCTClinical Trials
  72. Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci U S A. 2015 Feb 03; 112(5):1547-52. PMID: 25605928; PMCID: PMC4321320.
    Citations: 58     Fields:    Translation:HumansCTClinical Trials
  73. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63. PMID: 25535693.
    Citations: 54     Fields:    Translation:Humans
  74. Piotrowska Z, Scribner E, Temel B, Heist RS, Sequist LV, Temel JS. Retrospective chart review of end-of-life (EOL) care in patients with metastatic lung cancer harboring EGFR mutations. J Clin Oncol. 2014 Nov; 32(31_suppl):126. PMID: 28142731.
    Citations:    
  75. Azzoli CG, Engelman J, Fidias P, Gainor JF, Heist RS, Lamont EB, Lennes IT, Rosovsky RP, Sequist LV, Shaw AT, Temel JS. Genotyping lung cancer is an investment in the future. J Clin Oncol. 2014 Nov 01; 32(31):3576-7. PMID: 25199750.
    Citations: 2     Fields:    Translation:Humans
  76. Izar B, Zhou H, Heist RS, Azzoli CG, Muzikansky A, Scribner EE, Bernardo LA, Dias-Santagata D, Iafrate AJ, Lanuti M. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. J Thorac Oncol. 2014 Sep; 9(9):1363-9. PMID: 25122432.
    Citations: 36     Fields:    Translation:Humans
  77. Zhao Y, Wei Q, Hu L, Chen F, Hu Z, Heist RS, Su L, Amos CI, Shen H, Christiani DC. Polymorphisms in MicroRNAs are associated with survival in non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2014 Nov; 23(11):2503-11. PMID: 25103824.
    Citations: 12     Fields:    Translation:Humans
  78. Pu X, Hildebrandt MA, Lu C, Roth JA, Stewart DJ, Zhao Y, Heist RS, Ye Y, Chang DW, Su L, Minna JD, Lippman SM, Spitz MR, Christiani DC, Wu X. Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy. Clin Pharmacol Ther. 2014 Sep; 96(3):360-369. PMID: 24755914; PMCID: PMC4141040.
    Citations: 13     Fields:    Translation:Humans
  79. Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, Mino-Kenudson M, Wong KK, Engelman JA. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res. 2014 Jun 01; 74(11):3146-56. PMID: 24675361.
    Citations: 42     Fields:    Translation:HumansAnimalsCells
  80. Kinsey CM, Estepar RS, Zhao Y, Yu X, Diao N, Heist RS, Wain JC, Mark EJ, Washko G, Christiani DC. Invasive adenocarcinoma of the lung is associated with the upper lung regions. Lung Cancer. 2014 May; 84(2):145-50. PMID: 24598367.
    Citations: 16     Fields:    Translation:Humans
  81. Heist RS, Wang X, Hodgson L, Otterson GA, Stinchcombe TE, Gandhi L, Villalona-Calero MA, Watson P, Vokes EE, Socinski MA. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Feb; 9(2):214-21. PMID: 24419419.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  82. Besse B, Heist RS, Papadmitrakopoulou VA, Camidge DR, Beck JT, Schmid P, Mulatero C, Miller N, Dimitrijevic S, Urva S, Pylvaenaeinen I, Petrovic K, Johnson BE. A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. Ann Oncol. 2014 Feb; 25(2):505-11. PMID: 24368401.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  83. Heist R, Azzoli CG. Adjuvant therapy for a 3.9-cm adenocarcinoma of the lung. Oncologist. 2013; 18(12):1258-61. PMID: 24277772.
    Citations:    Fields:    Translation:Humans
  84. Brunner AM, Costa DB, Heist RS, Garcia E, Lindeman NI, Sholl LM, Oxnard GR, Johnson BE, Hammerman PS. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol. 2013 Nov; 8(11):1434-7. PMID: 24128713.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  85. Renouf DJ, Zhai R, Sun B, Xu W, Cheung WY, Heist RS, Kulke MH, Cescon D, Asomaning K, Marshall AL, Li S, Christiani DC, Liu G. Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma. J Gastroenterol Hepatol. 2013 Sep; 28(9):1482-8. PMID: 23735059.
    Citations: 4     Fields:    Translation:Humans
  86. Izar B, Sequist L, Lee M, Muzikansky A, Heist R, Iafrate J, Dias-Santagata D, Mathisen D, Lanuti M. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. Ann Thorac Surg. 2013 Sep; 96(3):962-8. PMID: 23932319.
    Citations: 43     Fields:    Translation:Humans
  87. Onozato ML, Kovach AE, Yeap BY, Morales-Oyarvide V, Klepeis VE, Tammireddy S, Heist RS, Mark EJ, Dias-Santagata D, Iafrate AJ, Yagi Y, Mino-Kenudson M. Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis. Am J Surg Pathol. 2013 Feb; 37(2):287-94. PMID: 23095504.
    Citations: 48     Fields:    Translation:HumansCells
  88. Goldberg SB, Willers H, Heist RS. Multidisciplinary management of small cell lung cancer. Surg Oncol Clin N Am. 2013 Apr; 22(2):329-43. PMID: 23453338.
    Citations: 8     Fields:    Translation:Humans
  89. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW, Merritt RE, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC, Gregory K, Hughes M. Small cell lung cancer. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):78-98. PMID: 23307984.
    Citations: 159     Fields:    Translation:Humans
  90. Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, Engelman JA, Iafrate AJ. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol. 2012 Dec; 7(12):1775-1780. PMID: 23154548.
    Citations: 94     Fields:    Translation:Humans
  91. Elena JW, Travis LB, Simonds NI, Ambrosone CB, Ballard-Barbash R, Bhatia S, Cerhan JR, Hartge P, Heist RS, Kushi LH, Lash TL, Morton LM, Onel K, Pierce JP, Robison LL, Rowland JH, Schrag D, Sellers TA, Seminara D, Shu XO, Thomas NE, Ulrich CM, Freedman AN. Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst. 2013 Jan 16; 105(2):85-94. PMID: 23197494; PMCID: PMC3545903.
    Citations: 25     Fields:    Translation:Humans
  92. Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res. 2013 Jan 15; 19(2):480-90. PMID: 23186780.
    Citations: 41     Fields:    Translation:Humans
  93. Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Oct; 7(10):1602-8. PMID: 22878749.
    Citations: 70     Fields:    Translation:HumansCTClinical Trials
  94. Hu L, Wu C, Zhao X, Heist R, Su L, Zhao Y, Han B, Cao S, Chu M, Dai J, Dong J, Shu Y, Xu L, Chen Y, Wang Y, Lu F, Jiang Y, Yu D, Chen H, Tan W, Ma H, Chen J, Jin G, Wu T, Lu D, Christiani DC, Lin D, Hu Z, Shen H. Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res. 2012 Oct 01; 18(19):5507-14. PMID: 22872573; PMCID: PMC3723686.
    Citations: 26     Fields:    Translation:Humans
  95. Heist RS, Sequist LV, Engelman JA. Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol. 2012 May; 7(5):924-33. PMID: 22722794.
    Citations: 60     Fields:    Translation:Humans
  96. Cheung WY, Zhai R, Bradbury P, Hopkins J, Kulke MH, Heist RS, Asomaning K, Ma C, Xu W, Wang Z, Hooshmand S, Su L, Christiani DC, Liu G. Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. Int J Cancer. 2012 Dec 01; 131(11):2478-86. PMID: 22422400.
    Citations: 11     Fields:    Translation:Humans
  97. Heist RS, Engelman JA. SnapShot: non-small cell lung cancer. Cancer Cell. 2012 Mar 20; 21(3):448.e2. PMID: 22439939.
    Citations: 103     Fields:    Translation:Humans
  98. Pirl WF, Greer JA, Traeger L, Jackson V, Lennes IT, Gallagher ER, Perez-Cruz P, Heist RS, Temel JS. Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care. J Clin Oncol. 2012 Apr 20; 30(12):1310-5. PMID: 22430269.
    Citations: 69     Fields:    Translation:HumansPHPublic Health
  99. Greer JA, Pirl WF, Jackson VA, Muzikansky A, Lennes IT, Heist RS, Gallagher ER, Temel JS. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol. 2012 Feb 01; 30(4):394-400. PMID: 22203758.
    Citations: 156     Fields:    Translation:Humans
  100. Mak RH, Alexander BM, Asomaning K, Heist RS, Liu CY, Su L, Zhai R, Ancukiewicz M, Napolitano B, Niemierko A, Willers H, Choi NC, Christiani DC. A single-nucleotide polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy. Cancer. 2012 Jul 15; 118(14):3654-65. PMID: 22144047; PMCID: PMC3312983.
    Citations: 13     Fields:    Translation:Humans
  101. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-2624. PMID: 22071650.
    Citations: 148     Fields:    Translation:Humans
  102. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC. Small cell lung cancer. J Natl Compr Canc Netw. 2011 Oct; 9(10):1086-113. PMID: 21975911.
    Citations: 13     Fields:    Translation:Humans
  103. Huang YT, Lin X, Liu Y, Chirieac LR, McGovern R, Wain J, Heist R, Skaug V, Zienolddiny S, Haugen A, Su L, Fox EA, Wong KK, Christiani DC. Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer. Proc Natl Acad Sci U S A. 2011 Sep 27; 108(39):16345-50. PMID: 21911369.
    Citations: 30     Fields:    Translation:HumansAnimals
  104. Huang YT, Lin X, Chirieac LR, McGovern R, Wain JC, Heist RS, Skaug V, Zienolddiny S, Haugen A, Su L, Christiani DC. Impact on disease development, genomic location and biological function of copy number alterations in non-small cell lung cancer. PLoS One. 2011; 6(8):e22961. PMID: 21829676.
    Citations: 10     Fields:    Translation:Humans
  105. Pirl WF, Traeger L, Greer JA, Bemis H, Gallagher E, Lennes I, Sequist L, Heist R, Temel JS. Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer. Oncologist. 2011; 16(9):1299-306. PMID: 21807767.
    Citations: 8     Fields:    Translation:Humans
  106. Zhai R, Zhao Y, Liu G, Ter-Minassian M, Wu IC, Wang Z, Su L, Asomaning K, Chen F, Kulke MH, Lin X, Heist RS, Wain JC, Christiani DC. Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: a case-only study. Cancer. 2012 Feb 01; 118(3):804-11. PMID: 21751195; PMCID: PMC3193872.
    Citations: 9     Fields:    Translation:HumansCells
  107. Greer JA, Pirl WF, Jackson VA, Lennes IT, Heist RS, Gallagher ER, Temel JS. Effect of early palliative care on chemotherapy utilization and end-of-life care in patients with metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2011 May 20; 29(15_suppl):6009. PMID: 28022016.
    Citations:    
  108. Sequist LV, Heist RS, Shaw AT, Fidias P, Temel JS, Lennes IT, Bast E, Waltman BA, Lanuti M, Muzikansky A, Mino-Kenudson M, Iafrate AJ, Borger DR, Dias-Santagata D, Engelman JA. SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. J Clin Oncol. 2011 May 20; 29(15_suppl):7518. PMID: 28023280.
    Citations:    
  109. Heist RS, Duda GD, Sahani D, Ancukiewicz M, Fidias P, Sequist LV, Shaw AT, Temel JS, Lennes IT, Neal JW, Pennell NA, Lynch TJ, Engelman JA, Jain RK. Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC. J Clin Oncol. 2011 May 20; 29(15_suppl):e18016. PMID: 28020106.
    Citations:    
  110. Coate LE, Zhai R, Xu W, Chen Z, Asomaning K, Kulke M, Heist RS, Christiani D, Liu G. Early adulthood obesity, cumulative smoking, and esophageal cancer survival. J Clin Oncol. 2011 May 20; 29(15_suppl):1546. PMID: 28024054.
    Citations:    
  111. Renouf DJ, Sun B, Zhai R, Xu W, Heist RS, Kulke M, Su L, Christiani DC, Liu G. Association of the MDM2 T309G polymorphism and gastroesophageal reflux disease (GERD) with overall survival (OS) in esophageal adenocarcinoma (EAC). J Clin Oncol. 2011 May 20; 29(15_suppl):10595. PMID: 28022019.
    Citations:    
  112. Wu IC, Zhao Y, Zhai R, Liu G, Ter-Minassian M, Asomaning K, Su L, Liu CY, Chen F, Kulke MH, Heist RS, Christiani DC. Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma. Neoplasia. 2011 Apr; 13(4):386-92. PMID: 21472143.
    Citations: 14     Fields:    Translation:Humans
  113. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23; 3(75):75ra26. PMID: 21430269.
    Citations: 1414     Fields:    Translation:Humans
  114. Wu IC, Zhao Y, Zhai R, Liu CY, Chen F, Ter-Minassian M, Asomaning K, Su L, Heist RS, Kulke MH, Liu G, Christiani DC. Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk. Carcinogenesis. 2011 Apr; 32(4):502-6. PMID: 21212151.
    Citations: 10     Fields:    Translation:Humans
  115. Yin M, Yan J, Voutsina A, Tibaldi C, Christiani DC, Heist RS, Rosell R, Booton R, Wei Q. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer. 2011 Jun; 72(3):370-7. PMID: 21075476.
    Citations: 18     Fields:    Translation:Humans
  116. Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Thorac Oncol. 2010 Nov; 5(11):1855-8. PMID: 20975380.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  117. Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, Temel JS, Fidias P, Brainerd V, Leopold L, Lynch TJ. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol. 2010 Oct; 5(10):1637-43. PMID: 20808253.
    Citations: 31     Fields:    Translation:HumansCTClinical Trials
  118. Liu CY, Wu MC, Chen F, Ter-Minassian M, Asomaning K, Zhai R, Wang Z, Su L, Heist RS, Kulke MH, Lin X, Liu G, Christiani DC. A Large-scale genetic association study of esophageal adenocarcinoma risk. Carcinogenesis. 2010 Jul; 31(7):1259-63. PMID: 20453000.
    Citations: 26     Fields:    Translation:Humans
  119. Zhai R, Chen F, Liu G, Su L, Kulke MH, Asomaning K, Lin X, Heist RS, Nishioka NS, Sheu CC, Wain JC, Christiani DC. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol. 2010 May 10; 28(14):2445-51. PMID: 20385987.
    Citations: 22     Fields:    Translation:Humans
  120. Temel JS, Greer JA, Admane S, Solis J, Cashavelly BJ, Doherty S, Heist R, Pirl WF. Code status documentation in the outpatient electronic medical records of patients with metastatic cancer. J Gen Intern Med. 2010 Feb; 25(2):150-3. PMID: 19894078.
    Citations: 20     Fields:    Translation:Humans
  121. Sequist LV, Fidias P, Heist RS, Ostler P, Muzikansky A, Lynch TJ. Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer. J Thorac Oncol. 2009 Sep; 4(9):1170-3. PMID: 19704338.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  122. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009 Sep 10; 27(26):4247-53. PMID: 19667264.
    Citations: 711     Fields:    Translation:Humans
  123. Bradbury PA, Kulke MH, Heist RS, Zhou W, Ma C, Xu W, Marshall AL, Zhai R, Hooshmand SM, Asomaning K, Su L, Shepherd FA, Lynch TJ, Wain JC, Christiani DC, Liu G. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics. 2009 Aug; 19(8):613-25. PMID: 19620936.
    Citations: 32     Fields:    Translation:HumansCells
  124. Bradbury PA, Zhai R, Ma C, Xu W, Hopkins J, Kulke MJ, Asomaning K, Wang Z, Su L, Heist RS, Lynch TJ, Wain JC, Christiani D, Liu G. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res. 2009 Jul 15; 15(14):4680-5. PMID: 19584152.
    Citations: 18     Fields:    Translation:Humans
  125. Cheung WY, Zhai R, Kulke MH, Heist RS, Asomaning K, Ma C, Wang Z, Su L, Lanuti M, Tanabe KK, Christiani DC, Liu G. Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk. Carcinogenesis. 2009 Aug; 30(8):1363-7. PMID: 19520791.
    Citations: 7     Fields:    Translation:Humans
  126. Heist RS, Fain J, Chinnasami B, Khan W, Molina J, Brainerd V, Leopold L, Lynch T. A phase I/II (P1/P2) study of AT-101 in combination with topotecan (T) in patients with relapsed or refractory small cell lung cancer (SCLC) after prior platinum-containing first-line chemotherapy. J Clin Oncol. 2009 May 20; 27(15_suppl):8106. PMID: 27964282.
    Citations:    
  127. Cheung WY, Zhai R, Kulke M, Heist R, Asomaning K, Ma C, Wang Z, Su L, Christiani D, Liu G. Epidermal growth factor (EGF) gene polymorphism, gastroesophageal reflux disease (GERD), and esophageal adenocarcinoma (EAC) risk. J Clin Oncol. 2009 May 20; 27(15_suppl):11029. PMID: 27963962.
    Citations:    
  128. Huang YT, Heist RS, Chirieac LR, Lin X, Skaug V, Zienolddiny S, Haugen A, Wu MC, Wang Z, Su L, Asomaning K, Christiani DC. Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J Clin Oncol. 2009 Jun 01; 27(16):2660-7. PMID: 19414679; PMCID: PMC2690391.
    Citations: 56     Fields:    Translation:HumansCells
  129. Cescon DW, Bradbury PA, Asomaning K, Hopkins J, Zhai R, Zhou W, Wang Z, Kulke M, Su L, Ma C, Xu W, Marshall AL, Heist RS, Wain JC, Lynch TJ, Christiani DC, Liu G. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clin Cancer Res. 2009 May 01; 15(9):3103-9. PMID: 19383811.
    Citations: 17     Fields:    Translation:Humans
  130. Bradbury PA, Zhai R, Hopkins J, Kulke MH, Heist RS, Singh S, Zhou W, Ma C, Xu W, Asomaning K, Ter-Minassian M, Wang Z, Su L, Christiani DC, Liu G. Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis. 2009 May; 30(5):793-8. PMID: 19321798; PMCID: PMC2675656.
    Citations: 29     Fields:    Translation:Humans
  131. Liu G, Cescon DW, Zhai R, Zhou W, Kulke MH, Ma C, Xu W, Su L, Asomaning K, Heist RS, Wain JC, Lynch TJ, Christiani DC. p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma. Dis Esophagus. 2010 Jan; 23(1):36-9. PMID: 19302219.
    Citations: 15     Fields:    Translation:Humans
  132. Heist RS, Christiani D. EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics. 2009 Jan; 10(1):59-68. PMID: 19102716.
    Citations: 20     Fields:    Translation:Humans
  133. Heist RS, Zhou W, Wang Z, Liu G, Neuberg D, Su L, Asomaning K, Hollis BW, Lynch TJ, Wain JC, Giovannucci E, Christiani DC. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol. 2008 Dec 01; 26(34):5596-602. PMID: 18936471; PMCID: PMC2651100.
    Citations: 53     Fields:    Translation:Humans
  134. Heist RS, Fidias P, Huberman M, Ardman B, Sequist LV, Temel JS, Lynch TJ. A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2008 Oct; 3(10):1153-8. PMID: 18827612.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  135. Zhai R, Liu G, Asomaning K, Su L, Kulke MH, Heist RS, Nishioka NS, Lynch TJ, Wain JC, Lin X, Christiani DC. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis. 2008 Dec; 29(12):2330-4. PMID: 18780893; PMCID: PMC2639251.
    Citations: 28     Fields:    Translation:Humans
  136. Ter-Minassian M, Zhai R, Asomaning K, Su L, Zhou W, Liu G, Heist RS, Lynch TJ, Wain JC, Lin X, De Vivo I, Christiani DC. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis. 2008 Nov; 29(11):2147-52. PMID: 18757527.
    Citations: 30     Fields:    Translation:Humans
  137. Asomaning K, Reid AE, Zhou W, Heist RS, Zhai R, Su L, Kwak EL, Blaszkowsky L, Zhu AX, Ryan DP, Christiani DC, Liu G. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res. 2008 Jun 15; 14(12):4010-5. PMID: 18559624.
    Citations: 15     Fields:    Translation:HumansCells
  138. Heist RS, Molina JR, Urba WJ, Mirshahidi H, Grunberg S, Maleski J, Brainerd V, Leopold L, Lynch TJ. Phase I/II study of AT-101 in combination with topotecan in patients with relapsed or refractory small cell lung cancer after prior platinum containing first line chemotherapy. J Clin Oncol. 2008 May 20; 26(15_suppl):19004. PMID: 27947948.
    Citations:    
  139. Cescon DW, Bradbury PA, Asomaning K, Zhai R, Kulke M, Su L, Heist RS, Wain JC, Lynch TJ, Christiani DC, Liu G. p53 Arg72Pro, MDM2 T309G, CCND1 G870A polymorphisms, histology and esophageal cancer prognosis. J Clin Oncol. 2008 May 20; 26(15_suppl):11033. PMID: 27947667.
    Citations:    
  140. Tse D, Zhai R, Zhou W, Heist RS, Asomaning K, Su L, Lynch TJ, Wain JC, Christiani DC, Liu G. Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Cancer Causes Control. 2008 Dec; 19(10):1077-83. PMID: 18478337.
    Citations: 43     Fields:    Translation:HumansCells
  141. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008 Mar; 18(3):317-23. PMID: 17985985.
    Citations: 70     Fields:    Translation:HumansCTClinical Trials
  142. Heist RS, Zhai R, Liu G, Zhou W, Lin X, Su L, Asomaning K, Lynch TJ, Wain JC, Christiani DC. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol. 2008 Feb 20; 26(6):856-62. PMID: 18281657.
    Citations: 48     Fields:    Translation:Humans
  143. Liu G, Wheatley-Price P, Zhou W, Park S, Heist RS, Asomaning K, Wain JC, Lynch TJ, Su L, Christiani DC. Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk. Int J Cancer. 2008 Feb 15; 122(4):915-8. PMID: 17957785.
    Citations: 20     Fields:    Translation:Humans
  144. Früh M, Zhou W, Zhai R, Su L, Heist RS, Wain JC, Nishioka NS, Lynch TJ, Shepherd FA, Christiani DC, Liu G. Polymorphisms of inflammatory and metalloproteinase genes, Helicobacter pylori infection and the risk of oesophageal adenocarcinoma. Br J Cancer. 2008 Feb 26; 98(4):689-92. PMID: 18253117.
    Citations: 7     Fields:    Translation:HumansCells
  145. Zhai R, Liu G, Zhou W, Su L, Heist RS, Lynch TJ, Wain JC, Asomaning K, Lin X, Christiani DC. Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res. 2008 Jan 15; 14(2):612-7. PMID: 18223238.
    Citations: 31     Fields:    Translation:Humans
  146. Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G. A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):204-11. PMID: 18199725.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  147. Heist RS, Liu G, Zhou W. Should oncologists measure the mRNA and protein expression levels of ERCC1 and RRM1 in non-small-cell lung cancer? Nat Clin Pract Oncol. 2007 Oct; 4(10):564-5. PMID: 17667918.
    Citations:    Fields:    
  148. Heist RS, Zhou W, Chirieac LR, Cogan-Drew T, Liu G, Su L, Neuberg D, Lynch TJ, Wain JC, Christiani DC. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol. 2007 Jun 01; 25(16):2243-7. PMID: 17538168.
    Citations: 22     Fields:    Translation:Humans
  149. Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K, Su L, Heist R, Lynch TJ, Christiani DC. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J. 2008 Apr; 8(2):129-38. PMID: 17375033.
    Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
  150. Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, Hollis BW, Wain JC, Lynch TJ, Giovannucci E, Su L, Christiani DC. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol. 2007 Feb 10; 25(5):479-85. PMID: 17290055.
    Citations: 68     Fields:    Translation:Humans
  151. Zhou W, Heist RS, Liu G, Asomaning K, Miller DP, Neuberg DS, Wain JC, Lynch TJ, Christiani DC. Second hand smoke exposure and survival in early-stage non-small-cell lung cancer patients. Clin Cancer Res. 2006 Dec 01; 12(23):7187-93. PMID: 17145845.
    Citations: 8     Fields:    Translation:HumansPHPublic Health
  152. Zhou W, Heist RS, Liu G, Neuberg DS, Asomaning K, Su L, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2006 Nov; 15(11):2239-45. PMID: 17119052.
    Citations: 27     Fields:    Translation:Humans
  153. Heist RS, Marshall AL, Liu G, Zhou W, Su L, Neuberg D, Lynch TJ, Wain J, Christiani DC. Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clin Cancer Res. 2006 Sep 15; 12(18):5448-53. PMID: 17000679.
    Citations: 10     Fields:    Translation:Humans
  154. Zhou W, Heist RS, Liu G, Park S, Neuberg DS, Asomaning K, Wain JC, Lynch TJ, Christiani DC. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer. 2006 Sep; 53(3):375-80. PMID: 16814423.
    Citations: 29     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Heist's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (381)
Explore
_
Co-Authors (171)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.